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Received March 28, 2012; accepted August 7, 2012AbstractBackground: Inflammatory bowel diseases (IBDs), Crohn’s disease, and ulcerative colitis are considered to be chronic inflammatory disorders
implicated with recurrent tissue damage to the intestine. There is a positive correlation between plateleteleukocyte aggregates and ischemic
vascular risk. There are limited data about the relationship between plateleteleukocyte aggregates and IBD. This study was designed to
determine whether plateleteleukocyte aggregates increase in IBD, and whether a relationship exists between the elevation of plateleteleukocyte
aggregates and disease activity.
Methods: A total of 20 patients with IBD (16 with ulcerative colitis and 4 with Crohn’s disease) and 20 healthy controls participated in our study.
Nine patients were in active-phase IBD, whereas 11 patients were in inactive phase. To show the presence of thrombocyte aggregates, the
monoclonal antibodies such as Isotype IgG1 mouse antihuman CD42b-PE (phycoerythrin) (Beckman Coulter IMI417), Isotype IgG1 mouse
antihuman CD45-FITC (fluorescein isothiocyanate) (Beckman Coulter IM0782), and Isotype IgG2a mouse antihuman CD45RO-FITC (Beck-
man Coulter IMI247) were used. Additionally, the values of plateleteneutrophil aggregates were measured in peripheral blood samples using
flow cytometry techniques.
Results: The levels of plateleteleukocyte aggregates in blood samples were found to be significantly higher during both the active and inactive
phases in patients with IBD. There were no statistically significant differences between active-phase and inactive-phase patients.
Conclusion: We determined that the patient group had significantly higher plateleteleukocyte aggregate levels compared with the control group.
This finding suggests that plateleteleukocyte aggregates may play a role in the development of IBD.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Inflammatory bowel diseases (IBDs), Crohn’s disease and
ulcerative colitis, are considered chronic inflammatory disor-
ders mediated by the immune response of the host and impli-
cated with recurrent tissue damage to the intestine. To date, their
pathogenesis has not yet been precisely determined.1* Corresponding author. Dr. Yavuz Tekelioglu, Division of Histology and
Embryology, Karadeniz Technical University, Medical Faculty, Trabzon,
Turkey.
E-mail address: ytekeli61@yahoo.com (Y. Tekelioglu).
1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.12.015During the activation phase of the disease in young pa-
tients, spontaneous thromboses can occur on different sites of
the body. Additionally, this exacerbation is accompanied by
thrombocytosis, which increases the risk of a thromboembolic
event.2 Various hemostatic pathologies were determined in
patients with IBD such as thrombocytosis, a decrease in
anticoagulant activities of antitrombin-3, protein-S, and tissue
plasminogen activator, an increase in the levels of fibrinogen,
plasma fibrinopeptid-A and factor 8, as well as an increase in
monocyte procoagulant activity. These features suggest the
presence of an underlying vascular inflammatory and pro-
thrombotic process.3hinese Medical Association. All rights reserved.
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aggregates (PLAs) and ischemic vascular risk.4 The results of
previous studies suggest that PLAs are more active than
circulating leukocytes alone.5e7 Leukocytes and platelets play
significant roles in the pathogenesis of IBD. Therefore, it is
reasonable to hypothesize that PLAs might play a role in IBD,
which is an inflammatory disorder.
P-selectin is located on platelet surfaces and has a key role
in the formation of PLAs. In addition to P-selectin, CD42b and
CD45 are also involved in this process. CD42b is the alpha
subunit of glycoprotein Ib. The binding of the glycoprotein
IbeIXeV complex in conjunction with the von Willebrand
factor facilitates initial platelet adhesion to vascular sub-
endothelium after vascular injury, and also initiates signaling
events within the platelet that lead to enhanced platelet acti-
vation, thrombosis, and hemostasis. CD45 is a family of
single-chain transmembraneous glycoproteins and are located
in all leukocytes. CD45 is also called the common leukocyte
antigen, protein tyrosine phosphatase receptor type C. Anti-
bodies recognizing a common epitope on all of the isoforms
are termed CD45, whereas those recognizing only individual
isoforms are termed CD45RA or CD45RO, etc. CD45RO is
located in memory T cells, and facilitates T cell activation.
There are limited data about the relationship between PLAs
and IBD. In our study, we measured the values of platelete
neutrophil aggregates in peripheral blood samples using flow
cytometry techniques in patients with IBD.
2. Methods
Our study included 20 patients whose follow-up took place
at the Istanbul Private Memorial Hospital. Among these pa-
tients, four had Crohn’s disease (mean age, 54.5 years)
whereas 16 had ulcerative colitis (mean age, 43.8 years).
When data from the two groups are combined, patient age
varied between 28 and 65 years, and mean age was 41.5 years.
Nine patients were in the active phase, whereas 11 patients
were in the inactive phase. For patients with Crohn’s disease,
clinical activity was measured with the Crohn’s disease ac-
tivity index, and that in patients with ulcerative colitis was
measured using the Rachmilewitz endoscopic index. Crohn’s
disease patients with a Best activity index score >1508 and
ulcerative colitis patient with a Rachmilewitz score 5 were
considered to have an active disease.9
All of the active-phase patients had ulcerative colitis.
Twenty age- and sex-matched healthy voluntary individuals
served as the control group (mean age, 39.8). Patients with a
history of peripheral vascular disease, hypertension, cardio-
pulmonary bypass, coronary angioplasty, chronic obstructive
pulmonary disease, hemodialysis, diabetes mellitus, or renal
insufficiency were excluded. Any patient and control group
member who had taken any drug treatment including ace-
tylsalicylic acid or nonsteroid anti-inflammatory drug, or
who smoked were also excluded. This study was approved
by the hospital administration of the Istanbul Private
Memorial Hospital. Study participants provided signed
informed consent.2.1. Blood samplingBlood samples were drawn from patients through a vein in
the region without stasis, and then passed into the siliconized
vacutainer tubes, which contained 3.6 mg of sterilized K2E
(Becton Dickinson).2.2. Monoclonal antibodiesTo show the presence of thrombocyte aggregates, the
following monoclonal antibodies were used in our study:
Isotype IgG1 mouse antihuman CD42b-PE (phycoerythrin)
(Beckman Coulter IMI417), Isotype IgG1 mouse antihuman
CD45-FITC (fluorescein isothiocyanate) (Beckman Coulter
IM0782), and Isotype IgG2a mouse antihuman CD45RO-
FITC (Beckman Coulter IMI247).2.3. Flow-cytometric analysisWe used a Beckman Coulter EPICS ELITE analyzer for
flow cytometric analysis. Each tube (CD42a/CD62P, CD42b/
CD62P) was separately prepared for patient and control group
blood samples and contained 20 mL of monoclonal antibody,
which was subsequently mixed with 20 mL of blood sample,
and finally incubated for 15 minutes at room temperature.
Then, these tubes were processed by a Coulter Multi Q
preparation device. Immunoprep A, B, and C solutions
(Immunoprep A: formic acidestabilizer; Immunoprep B: so-
dium carbonateechlorideesulfateestabilizer; and Immuno-
prep C: paraformaldehydeebuffers Coulter Immunoprep
reagent system PN7507950-D) were then added. After 15
minutes, the samples were ready for flow cytometric analysis.
On the second dot plot, another gating was performed on the
cell population that contained CD45 positive cells. In accor-
dance with this gating process, the PLAs that existed in the
marked area of CD45/CD42b, CD45RO/CD42b dot plot were
displayed and then analyzed (Fig. 1).2.4. Statistical analysisWe used a one-way ANOVA test with post hoc Bonferroni
test to evaluate the investigative data. A p value of <0.05 was
considered statistically significant.
3. Results
The levels of PLAs (CD45/CD42b and CD45RO/CD42b)
were found to be significantly higher in the patient group with
IBD than in the control group [mean value of 6.75  1.15%
(SEM) and 1.65  0.16% for the patient group and the control
group, respectively; p ¼ 0.0001]. The PLA values of nine
patients in the active phase of IBD were found to be signifi-
cantly higher when compared with those of the control
group (mean value of 8.15  1.92% and 1.65  0.16% for
active-phase patients and the control group, respectively;
p ¼ 0.0001). Similarly, the PLA values of 11 inactive-phase
patients were found to be significantly higher when
Fig. 1. Flow cytometric analysis for CD45 and CD42b.
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4.56  0.42% and 1.65  0.16% for inactive-phase patients
and the control group, respectively; p ¼ 0.0001).
When the inactive-phase and active-phase patient groups
were compared, the PLA values of the active-phase patient
group (8.15  1.92%) were higher than those of the inactive-
phase patient group (4.56  0.42%). The difference was found
to be statistically significant ( p ¼ 0.0001).4. Discussion
Using flow-cytometric techniques, we found that the values
of PLAs were significantly higher in the patient group than in
the control group.
After initiating the neutrophil chemotaxis process, the
hyperaggregable active platelets in IBD may amplify the in-
flammatory cascade. The P-selectin (CD62P) released by the
platelets facilitates the migration of neutrophils into the
inflammation area. Other mediators released by the active
platelets including platelet factor-4, platelet-activating factor,
seratonin, and 12-hydroxyeicosatetraenoic acids show re-
actions as a chemotactic factor for neutrophils. In addition,
platelet factor-4 stimulates the release of elastase from neu-
trophils. Active platelets can start the diapedesis process of
neutrophil by stimulating IL-8 release from the endothelium.
Circulating platelet aggregates may lead to the occlusion of
intestinal microveins. Moreover, thromboxane A2 may
contribute to the likelihood of ischemia after stimulating with
local vasoconstriction.10 The platelet aggregate values are
higher in patients with IBD in peripheral circulation. It is
stated that the cause of this elevation was platelet aggregation
that started in the mesenteric vessels.11
During the process of inflammation, platelets bind to leu-
kocytes to form PLAs. The first adhesion of platelets to neu-
trophils or monocytes occurs via the binding of P-selectin to
its specific ligand on the leukocyte surface, P-selectin glyco-
protein ligand-1. The stabilization of leukocyteeplatelet ag-
gregates occurs via the binding of leukocyte surface Mac-1 to
platelet surface glycoprotein Ib (GPIb), integrin aIIbb3, and/or
junctional adhesion molecule 3. It is thought that an increased
PLA value is a sensitive marker of inflammation and platelet
activity.12,13An increased number of PLAs occur in inflammatory states
such as diabetes mellitus, cystic fibrosis, asthma, pre-eclampsia,
nephrotic syndrome, sickle cell disease, and collagenous tissue
diseases. Additional research is necessary to clarify the rela-
tionship between PLAs and IBD.
In our study, we determined that significantly higher PLAs
existed in the patient group compared with the control group.
This finding suggests that PLAs may be important in the
pathogenesis of IBD.
We found that PLAs are significantly and statistically
higher both in the active- and inactive-phase patient groups
compared with the control group. When active- and inactive-
phase patients were compared, no statistically significant dif-
ference was found. This situation reflects the fact that the
abnormal hemostatic mechanism still prevailed, and patients
had not completely recovered although they had shown in-
dications of clinical remission.
Thus, it is reported that only 29% of patients in clinical
remission had also achieved an endoscopic remission.14
Similar to our study, Irving et al15 stated that the formation of
PLAs was part of the increased platelet activation and played a
role in IBD pathogenesis. The relationship between PLA for-
mation and clinical and laboratory disease activity markers
(platelet count, white blood cell count, activation of platelet and
neutrophil) has not yet been established.15 There had not been
any definitive study done on this subject until Irving et al re-
ported the results of their investigation. Our study is another
example showing that PLAs play a role in IBD pathogenesis.
One of the limitations of our study is the sample size.
However, when we excluded those patients with factors that
raise PLAs, the sample size decreased. We have to emphasize
only the PLA increase in IBD patients without any comor-
bidities. Formation of PLAs is increased in several inflam-
matory conditions. This may result from platelet and
neutrophil activation, but may also contribute to the inflam-
matory process.15 It is strongly believed that PLAs play a role
in IBD pathogenesis; however, additional studies must be
completed to evaluate whether the increase in PLAs are the
result or cause of IBD.
Our results suggest that the agents that may prevent PLA
formation or efficiency could actually be of use in the treatment
of IBD. Accordingly, it was shown that administration of a re-
combinant soluble P-selectin glycoprotein ligand-1 preserved
185Y. Tekelioglu et al. / Journal of the Chinese Medical Association 76 (2013) 182e185vascular endothelial function.16 When considering the diffi-
culties associated with the treatment of IBD and the nature of
such a disease, which is characterized by irregular disease
progress and exacerbation, comprehensive studies of PLAs are
needed in order to develop new therapeutic strategies.
References
1. Radford Smith G, Jewell DP. Cytokines and inflammatory bowel disease.
Baillieres Clin Gastroenterol 1996;10:151e64.
2. Collins CE, Cahili MR, Newland AC, Rampton DS. Platelets circulate in
an activated state in inflammatory bowel disease. Gastroenterology
1994;106:840e5.
3. Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM,
Lewis AAM, et al. Pathogenesis of Crohn’s disease: multifocal gastroin-
testinal infarction. Lancet 1989;2:1057e62.
4. de Gaetano G, Cerletti C, Evangelista V. Recent advances in platelete
polymorphonuclear leukocyte interaction. Haemostasis 1999;29:41e9.
5. Peters MJ, Dixon G, Kotowicz KT, Hatch DJ, Heyderman RS, KLein NJ.
Circulating plateleteneutrophil complexes represent a subpopulation of
activated neutrophils primed for adhesion, phagocytosis and intracellular
killing. Br J Haematol 1999;106:391e9.
6. Ott I, Neumann FJ, Gawaz M, Schmitt M, Scho¨mig A. Increased neu-
trophileplatelet adhesion in patients with unstable angina. Circulation
1996;94:1239e46.
7. Neumann FJ, Marx N, Gawaz M, Brand K, Ott I, Rokitta C, et al. In-
duction of cytokine expression in leukocytes by binding of thrombin-
stimulated platelets. Circulation 1997;95:2387e94.8. Best WR, Becktel JM, Singleton JW, Kern Jr F. Development of a Crohn’s
disease activity index. National Cooperative Crohn’s Disease Study.
Gastroenterology 1976;70:439e44.
9. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sul-
phasalazine in the treatment of active ulcerative colitis: a randomised trial.
BMJ 1989;298:82e6.
10. Simmonds NJ, Ailen RE, Stevens TR, Van Someren RN, Blake DR,
Rampton DS. Chemiluminescence assay of mucosal reactive oxygen metab-
olites in inflammatory bowel disease. Gastroenterology 1992;103:186e96.
11. Collins CE, Rampton DS, Rogers J, Williams NS. Platelet aggregation and
neutrophil sequestration in the mesenteric circulation in inflammatory
bowel disease. Eur J Gastroenterol Hepatol 1997;9:1213e7.
12. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ,
Loscalzo J, et al. In vivo tracking of platelets: circulating degranulated
platelets rapidly lose surface P-selectin but continue to circulate and
function. Proc Natl Acad Sci U S A 1996;93:11877e82.
13. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI.
Circulating monocyteplatelet aggregates are a more sensitive marker of
in vivo platelet activation than platelet surface P-selectin: studies in ba-
boons, human coronary intervention, and human acute myocardial
infarction. Circulation 2001;104:1533e7.
14. Modigliani R, Mary JY, Simon JF, Cortot A, Soule J, Gendre JP, et al.
Clinical, biological and endoscopic picture of attacks of Crohn’s disease.
Gastroenterology 1990;98:811e8.
15. Irving PM, Macey MG, Shah U, Webb L, Langmead L, Rampton DS.
Formation of plateleteleukocyte aggregates in inflammatory bowel dis-
ease. Inflamm Bowel Dis 2004;10:361e72.
16. Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM. Recombinant
soluble P-selectin glycoprotein ligand-1 protects against myocardial
ischemic reperfusion injury in cats. Cardiovasc Res 1999;41:65e76.
